Syros Pharmaceuticals (SYRS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

SYRS Stock Forecast

Syros Pharmaceuticals stock forecast is as follows: an average price target of $10.00 (represents a 4514.67% upside from SYRS’s last price of $0.22) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

SYRS Price Target

The average price target for Syros Pharmaceuticals (SYRS) is $10.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $5.00. This represents a potential 4514.67% upside from SYRS's last price of $0.22.

SYRS Analyst Ratings

Buy

According to 6 Wall Street analysts, Syros Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SYRS stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Syros Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 23, 2024	Edward Tenthoff	Piper Sandler	$5.00	$2.47	102.43%	2207.34%
Jun 26, 2024	Edward Tenthoff	Piper Sandler	$13.00	$5.70	128.07%	5899.08%
Jun 26, 2024	Andrew Fein	H.C. Wainwright	$15.00	$5.70	163.16%	6822.01%
Aug 09, 2022	Mark Breidenbach	Oppenheimer	$30.00	$9.27	223.52%	13744.02%

The latest Syros Pharmaceuticals stock forecast, released on Oct 23, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $5.00, which represents a 102.43% increase from the stock price at the time of the forecast ($2.47), and a 2207.34% increase from SYRS last price ($0.22).

Syros Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	3
Avg Price Target	-	$5.00	$11.00
Last Closing Price	$0.22	$0.22	$0.22
Upside/Downside	-100.00%	2207.34%	4976.14%

In the current month, the average price target of Syros Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Syros Pharmaceuticals's last price of $0.22. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 13, 2024	JMP Securities	Market Outperform	Perform	Downgrade
Oct 23, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 26, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 26, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 26, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 25, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Jan 05, 2023	Piper Sandler	Overweight	Overweight	Hold
Sep 19, 2022	Piper Sandler	Overweight	Overweight	Hold
Aug 09, 2022	Oppenheimer	Outperform	Outperform	Hold
May 17, 2022	Alliance Global Partners	Buy	Buy	Hold
May 03, 2022	Raymond James	Outperform	Outperform	Hold
May 28, 2021	Oppenheimer		Buy	Initialise

Syros Pharmaceuticals's last stock rating was published by JMP Securities on Nov 13, 2024. The company Downgrade its SYRS rating from "Market Outperform" to "Perform".

Syros Pharmaceuticals Financial Forecast

Syros Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$3.76M	$2.83M	$2.95M	$-5.47M	$3.89M	$6.28M	$5.47M	$7.80M	$5.70M	$5.16M	$4.83M	$5.70M	$3.83M	$3.19M	$2.38M	$508.00K	$558.00K	$462.00K	$454.00K	$370.00K	$1.10M
Avg Forecast	-	-	-	-	$450.00K	$360.00K	$460.00K	$720.00K	$2.00M	$3.94M	$3.50M	$3.30M	$3.85M	$5.18M	$4.74M	$4.92M	$4.81M	$4.49M	$4.13M	$2.67M	$2.64M	$2.54M	$1.90M	$1.87M	$691.29K	$441.17K	$430.29K	$430.29K	$300.63K	$1.33M
High Forecast	-	-	-	-	$450.00K	$360.00K	$460.00K	$720.00K	$2.92M	$3.94M	$3.50M	$3.30M	$3.85M	$5.18M	$4.74M	$4.92M	$4.81M	$4.49M	$4.13M	$2.67M	$2.64M	$2.54M	$1.90M	$1.87M	$691.29K	$441.17K	$430.29K	$430.29K	$360.75K	$1.59M
Low Forecast	-	-	-	-	$450.00K	$360.00K	$460.00K	$720.00K	$1.08M	$3.94M	$3.50M	$3.30M	$3.85M	$5.18M	$4.74M	$4.92M	$4.81M	$4.49M	$4.13M	$2.67M	$2.64M	$2.54M	$1.90M	$1.87M	$691.29K	$441.17K	$430.29K	$430.29K	$240.50K	$1.06M
# Analysts	-	-	-	-	4	2	1	1	3	1	1	1	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	16
Surprise %	-	-	-	-	-	-	-	-	-	0.95%	0.81%	0.89%	-1.42%	0.75%	1.32%	1.11%	1.62%	1.27%	1.25%	1.81%	2.16%	1.50%	1.68%	1.27%	0.73%	1.26%	1.07%	1.06%	1.23%	0.83%

Syros Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.00M, with a low forecast of $1.08M, and a high forecast of $2.92M. SYRS's average Quarter revenue forecast represents a -46.84% decrease compared to the company's last Quarter revenue of $3.76M (Sep 23).

Syros Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	-	-	-	4	2	1	1	3	1	1	1	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	16
EBITDA	-	-	-	-	-	-	-	-	-	$-34.64M	$-34.00M	$-30.80M	$-33.63M	$-38.34M	$-32.93M	$-25.87M	$-22.05M	$-24.28M	$-20.77M	$-12.53M	$-29.36M	$-18.72M	$-16.44M	$-16.48M	$-18.83M	$-19.15M	$-18.81M	$-15.93M	$-14.07M	$-11.15M
Avg Forecast	-	-	-	-	$-450.00K	$-360.00K	$-460.00K	$-720.00K	$-2.00M	$-3.94M	$-3.50M	$-3.30M	$-3.85M	$-5.18M	$-4.74M	$-4.92M	$-4.81M	$-4.49M	$-4.13M	$-16.92M	$-2.64M	$-2.54M	$-1.90M	$-18.02M	$-691.29K	$-441.17K	$-430.29K	$-18.16M	$-10.83M	$-13.04M
High Forecast	-	-	-	-	$-450.00K	$-360.00K	$-460.00K	$-720.00K	$-1.08M	$-3.94M	$-3.50M	$-3.30M	$-3.85M	$-5.18M	$-4.74M	$-4.92M	$-4.81M	$-4.49M	$-4.13M	$-13.53M	$-2.64M	$-2.54M	$-1.90M	$-14.41M	$-691.29K	$-441.17K	$-430.29K	$-14.53M	$-8.66M	$-10.43M
Low Forecast	-	-	-	-	$-450.00K	$-360.00K	$-460.00K	$-720.00K	$-2.92M	$-3.94M	$-3.50M	$-3.30M	$-3.85M	$-5.18M	$-4.74M	$-4.92M	$-4.81M	$-4.49M	$-4.13M	$-20.30M	$-2.64M	$-2.54M	$-1.90M	$-21.62M	$-691.29K	$-441.17K	$-430.29K	$-21.80M	$-12.99M	$-15.65M
Surprise %	-	-	-	-	-	-	-	-	-	8.79%	9.71%	9.33%	8.74%	7.40%	6.95%	5.25%	4.59%	5.41%	5.02%	0.74%	11.13%	7.36%	8.64%	0.91%	27.24%	43.41%	43.71%	0.88%	1.30%	0.86%

undefined analysts predict SYRS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Syros Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Syros Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	-	-	-	4	2	1	1	3	1	1	1	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	16
Net Income	-	-	-	-	-	-	-	-	-	$-40.14M	-	$-14.92M	$27.57M	$-21.05M	$-35.19M	$-23.64M	$-24.80M	$-26.03M	$-22.49M	$-14.23M	$-30.13M	$-19.49M	$-17.20M	$-17.23M	$-19.73M	$-19.79M	$-19.45M	$-16.46M	$-14.46M	$-11.52M
Avg Forecast	$-16.69M	$-17.28M	$-18.85M	$-21.21M	$-27.19M	$-26.56M	$-30.14M	$-33.27M	$-44.92M	$-44.77M	$-44.30M	$-41.17M	$-48.11M	$-152.52M	$-160.22M	$-184.57M	$-181.76M	$-171.80M	$-145.30M	$-19.21M	$-195.86M	$-151.19M	$-158.55M	$-18.83M	$-180.64M	$-181.29M	$-161.00M	$-18.77M	$-11.13M	$-13.47M
High Forecast	$-16.69M	$-17.28M	$-18.85M	$-21.21M	$-25.05M	$-26.56M	$-30.14M	$-33.27M	$-39.08M	$-44.77M	$-44.30M	$-41.17M	$-48.11M	$-152.52M	$-160.22M	$-184.57M	$-181.76M	$-171.80M	$-145.30M	$-15.37M	$-195.86M	$-151.19M	$-158.55M	$-15.06M	$-180.64M	$-181.29M	$-161.00M	$-15.02M	$-8.90M	$-10.77M
Low Forecast	$-16.69M	$-17.28M	$-18.85M	$-21.21M	$-28.98M	$-26.56M	$-30.14M	$-33.27M	$-50.40M	$-44.77M	$-44.30M	$-41.17M	$-48.11M	$-152.52M	$-160.22M	$-184.57M	$-181.76M	$-171.80M	$-145.30M	$-23.05M	$-195.86M	$-151.19M	$-158.55M	$-22.59M	$-180.64M	$-181.29M	$-161.00M	$-22.53M	$-13.35M	$-16.16M
Surprise %	-	-	-	-	-	-	-	-	-	0.90%	-	0.36%	-0.57%	0.14%	0.22%	0.13%	0.14%	0.15%	0.15%	0.74%	0.15%	0.13%	0.11%	0.91%	0.11%	0.11%	0.12%	0.88%	1.30%	0.86%

Syros Pharmaceuticals's average Quarter net income forecast for Mar 23 is $-41.17M, with a range of $-41.17M to $-41.17M. SYRS's average Quarter net income forecast represents a -249.29% decrease compared to the company's last Quarter net income of $27.57M (Dec 22).

Syros Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	-	-	-	4	2	1	1	3	1	1	1	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	16
SG&A	-	-	-	-	-	-	-	-	-	$7.76M	$7.22M	$7.41M	$7.33M	$8.08M	$6.95M	$6.95M	$6.43M	$5.35M	$5.52M	$5.74M	$5.89M	$5.15M	$5.13M	$5.15M	$6.40M	$5.02M	$5.20M	$4.87M	$4.08M	$3.09M
Avg Forecast	-	-	-	-	$1.62M	$1.30M	$1.66M	$2.60M	$7.22M	$14.22M	$12.63M	$11.92M	$13.90M	$18.70M	$17.11M	$17.77M	$17.35M	$16.20M	$14.92M	$9.64M	$9.52M	$9.18M	$6.87M	$6.76M	$2.49M	$1.59M	$1.55M	$1.55M	$1.08M	$4.78M
High Forecast	-	-	-	-	$1.62M	$1.30M	$1.66M	$2.60M	$10.53M	$14.22M	$12.63M	$11.92M	$13.90M	$18.70M	$17.11M	$17.77M	$17.35M	$16.20M	$14.92M	$9.64M	$9.52M	$9.18M	$6.87M	$6.76M	$2.49M	$1.59M	$1.55M	$1.55M	$1.30M	$5.74M
Low Forecast	-	-	-	-	$1.62M	$1.30M	$1.66M	$2.60M	$3.91M	$14.22M	$12.63M	$11.92M	$13.90M	$18.70M	$17.11M	$17.77M	$17.35M	$16.20M	$14.92M	$9.64M	$9.52M	$9.18M	$6.87M	$6.76M	$2.49M	$1.59M	$1.55M	$1.55M	$867.99K	$3.83M
Surprise %	-	-	-	-	-	-	-	-	-	0.55%	0.57%	0.62%	0.53%	0.43%	0.41%	0.39%	0.37%	0.33%	0.37%	0.60%	0.62%	0.56%	0.75%	0.76%	2.57%	3.15%	3.35%	3.13%	3.76%	0.64%

Syros Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $7.22M, based on 3 Wall Street analysts, with a range of $3.91M to $10.53M. The forecast indicates a -7.03% fall compared to SYRS last annual SG&A of $7.76M (Sep 23).

Syros Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	-	-	-	4	2	1	1	3	1	1	1	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	16
EPS	-	-	-	-	-	-	-	-	-	$-1.43	$-1.30	$-0.54	$5.99	$-2.24	$-5.51	$-3.75	$-3.94	$-4.14	$-3.58	$-2.32	$-4.91	$-4.26	$-3.76	$-3.92	$-4.49	$-4.66	$-4.67	$-4.87	$-4.77	$-4.92
Avg Forecast	$-0.42	$-0.44	$-0.48	$-0.54	$-0.69	$-0.68	$-0.77	$-0.85	$-1.14	$-1.14	$-1.13	$-1.05	$-1.23	$-3.88	$-4.08	$-4.70	$-4.63	$-4.38	$-3.70	$-4.64	$-4.99	$-3.85	$-4.04	$-4.21	$-4.60	$-4.62	$-4.10	$-5.60	$-0.30	$-0.69
High Forecast	$-0.42	$-0.44	$-0.48	$-0.54	$-0.64	$-0.68	$-0.77	$-0.85	$-1.00	$-1.14	$-1.13	$-1.05	$-1.23	$-3.88	$-4.08	$-4.70	$-4.63	$-4.38	$-3.70	$-4.64	$-4.99	$-3.85	$-4.04	$-4.21	$-4.60	$-4.62	$-4.10	$-5.60	$-0.24	$-0.55
Low Forecast	$-0.42	$-0.44	$-0.48	$-0.54	$-0.74	$-0.68	$-0.77	$-0.85	$-1.28	$-1.14	$-1.13	$-1.05	$-1.23	$-3.88	$-4.08	$-4.70	$-4.63	$-4.38	$-3.70	$-4.64	$-4.99	$-3.85	$-4.04	$-4.21	$-4.60	$-4.62	$-4.10	$-5.60	$-0.36	$-0.83
Surprise %	-	-	-	-	-	-	-	-	-	1.25%	1.15%	0.52%	-4.89%	0.58%	1.35%	0.80%	0.85%	0.95%	0.97%	0.50%	0.98%	1.11%	0.93%	0.93%	0.98%	1.01%	1.14%	0.87%	15.89%	7.13%

According to 1 Wall Street analysts, Syros Pharmaceuticals's projected average Quarter EPS for Mar 23 is $-1.05, with a low estimate of $-1.05 and a high estimate of $-1.05. This represents a -117.50% decrease compared to SYRS previous annual EPS of $5.99 (Dec 22).

Syros Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SYRS	Syros Pharmaceuticals	$0.21	$10.00	4661.90%	Buy
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
KROS	Keros Therapeutics	$18.00	$102.00	466.67%	Buy
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
RGNX	REGENXBIO	$8.47	$29.75	251.24%	Buy
CHRS	Coherus BioSciences	$1.71	$6.00	250.88%	Hold
KZR	Kezar Life Sciences	$6.52	$17.50	168.40%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
IDYA	IDEAYA Biosciences	$26.33	$53.33	102.54%	Buy
BOLT	Bolt Biotherapeutics	$0.54	$1.00	85.19%	Hold
CRNX	Crinetics Pharmaceuticals	$55.37	$69.00	24.62%	Buy
XNCR	Xencor	$25.04	$30.00	19.81%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy

SYRS Forecast FAQ

Is Syros Pharmaceuticals a good buy?

Yes, according to 6 Wall Street analysts, Syros Pharmaceuticals (SYRS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of SYRS's total ratings.

What is SYRS's price target?

Syros Pharmaceuticals (SYRS) average price target is $10 with a range of $5 to $15, implying a 4514.67% from its last price of $0.217. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Syros Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for SYRS stock, the company can go up by 4514.67% (from the last price of $0.217 to the average price target of $10), up by 6822.01% based on the highest stock price target, and up by 2207.34% based on the lowest stock price target.

Can Syros Pharmaceuticals stock reach $0?

SYRS's average twelve months analyst stock price target of $10 supports the claim that Syros Pharmaceuticals can reach $0 in the near future.

What are Syros Pharmaceuticals's analysts' financial forecasts?

Syros Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.99M (high $1.99M, low $1.99M), average EBITDA is $-1.99M (high $-1.99M, low $-1.99M), average net income is $-117M (high $-115M, low $-119M), average SG&A $7.18M (high $7.18M, low $7.18M), and average EPS is $-2.983 (high $-2.929, low $-3.029). SYRS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-74.023M (high $-74.023M, low $-74.023M), average SG&A $0 (high $0, low $0), and average EPS is $-1.885 (high $-1.885, low $-1.885).

Did the SYRS's actual financial results beat the analysts' financial forecasts?

Based on Syros Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $9.94M, which missed the average analysts forecast of $12.74M by -22.02%. Apple's EBITDA was $-129M, beating the average prediction of $-12.742M by 912.33%. The company's net income was $0, missing the average estimation of $-175M by -100.00%. Apple's SG&A was $28.28M, missing the average forecast of $45.99M by -38.50%. Lastly, the company's EPS was $-5.81, beating the average prediction of $-4.46 by 30.26%. In terms of the last quarterly report (Sep 2023), Syros Pharmaceuticals's revenue was $3.76M, missing the average analysts' forecast of $3.94M by -4.52%. The company's EBITDA was $-34.636M, beating the average prediction of $-3.94M by 779.09%. Syros Pharmaceuticals's net income was $-40.143M, missing the average estimation of $-44.767M by -10.33%. The company's SG&A was $7.76M, missing the average forecast of $14.22M by -45.40%. Lastly, the company's EPS was $-1.43, beating the average prediction of $-1.14 by 25.44%